Wound care in America is undergoing a fundamental transformation. Effective January 1, 2026, the Centers for Medicare & Medicaid Services (CMS) implemented the most consequential changes to skin substitute reimbursement in the program’s history — and the legal and compliance risks for providers who are not prepared are significant. Here is what every wound care provider needs to understand about the current regulatory landscape.
Medicare Part B spending on skin substitutes — formally known as cellular and/or tissue-based products (CTPs) or Cellular, Acellular, and Matrix-Like Products (CAMPs) — exploded from $252 million in 2019 to over $10 billion in 2024. That is a nearly 40-fold increase in five years.
CMS attributed this surge primarily to escalating product launch prices billed under the Average Sales Price (ASP) plus 6% methodology — a payment structure originally designed for traditional biologicals. The agency’s response is a restructured payment model that shifts financial risk squarely onto providers.
Effective January 1, 2026, CMS implemented two changes that reshape how wound care products are paid for:
Critically, the application procedure and the product are now billed separately, and this separation applies uniformly across Hospital Outpatient Departments (HOPDs), physician offices, and patient homes. The low-cost HCPCS codes C5271–C5278 have been deleted; high-cost application codes 15271–15278 now apply in all settings.
The 2026 rule changes create several high-risk compliance areas that our attorneys are already seeing generate government scrutiny:
Medicare now reimburses only for the units of a CTP actually applied to the patient. Discarded product is non-billable under any circumstance — it cannot be included in billed units and cannot be claimed with the JW modifier. Billing for waste constitutes a false claim.
These modifiers apply only to drugs and biologicals payable under Part B. Since CTPs are now classified as incident-to supplies, applying JW or JZ to a CTP claim is a billing error with False Claims Act exposure.
Existing Local Coverage Determinations (LCDs) require that a wound fail to respond to at least 30 days of standard of care before a CTP is applied, with full documentation of wound baseline, treatment type, and patient response. Gaps in this record are among the most common audit findings we encounter.
Medicare LCDs cap CTP applications at ten per ulcer within a 12-week episode. Exceeding these limits without documented medical justification is a significant audit trigger.
Compounding the payment reforms, CMS launched the Wasteful and Inappropriate Service Reduction (WISeR) model on January 1, 2026, introducing prior authorization requirements for skin substitutes in Medicare fee-for-service. The model is currently piloted in six states, New Jersey, Ohio, Oklahoma, Texas, Arizona, and Washington, but expansion is expected. Providers in these states must build prior authorization workflows into their standard operating procedures or face non-payment.
The flat-rate reimbursement model creates a predictable margin tied directly to product acquisition cost — but only for providers who have their compliance infrastructure in place. We recommend the following:
Chapman Law Group represents healthcare providers across the country in Medicare and Medicaid compliance matters, billing audits, False Claims Act defense, and regulatory counseling. Our healthcare attorneys understand the clinical realities of wound care and the legal framework governing it.
If your practice is navigating the 2026 reimbursement changes, facing a Medicare audit, or seeking proactive compliance guidance, call Chapman Law Group today to get a free consultation.
"*" indicates required fields
Michigan Office
880 W. Long Lake Road, Suite 150
Troy, MI 48098
Phone: (248) 644-6326
Our federal criminal defense team helped secure a victory in the United States vs. Bothra case, equaling a $450M Acquittal. Here’s how they..
Our Michigan healthcare regulatory and licensing lawyers negotiated to permit the physician to voluntarily resign from the employment contract without any reporting to the NPDB or the state licensing board.
After testing positive for alcohol at levels that indicated binge drinking, our healthcare licensing attorneys submitted the polygraph results to the DOH along with letters from her medical providers attesting to her fitness to practice.
The family of a deceased Michigan Department of Corrections inmate sued several corrections officers and medical providers, alleging they failed to provide adequate treatment for the inmate’s asthma.
